Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. USO
2. LAD
3. ROIV
4. ASML
5. DKNG
6. BSX
7. ODFL
8. NVS
9. AHR
10. ALV

Go back to Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
(NASDAQ: AXSM) Delayed: 206.68 --0 (-0%)
Previous Close $206.68    52 Week High $15.74 
Open $206.68    52 Week Low $5.37 
Day High $206.68    P/E N/A 
Day Low $206.68    EPS $0.00 
Volume 47